nach oben

Erschienen in:

01.02.2008 | Epidemiology

Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk

verfasst von: Yong Zhu, Richard G. Stevens, Derek Leaderer, Aaron Hoffman, Theodore Holford, Yawei Zhang, Heather N. Brown, Tongzhang Zheng

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Three known non-synonymous polymorphisms (Ala394Thr, Ser471Leu and Pro690Ala) in the largest circadian gene, Neuronal PAS domain protein 2 (NPAS2), were genotyped in a breast cancer case-control study conducted in Connecticut, USA (431 cases and 476 controls). We found that women with the heterozygous Ala394Thr genotype were significantly associated with breast cancer risk compared to those with the common homozygous Ala394Ala (OR = 0.61, 0.46–0.81, P = 0.001). This is the first evidence demonstrating a role of the circadian gene NPAS2 in human breast cancer, suggesting that genetic variations in circadian genes might be a novel panel of biomarkers for breast cancer risk.

Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562PubMedCrossRef

Schernhammer ES, Laden F, Speizer FE et al (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93:1563–1568PubMedCrossRef

Lie JA, Roessink J, Kjaerheim K (2006) Breast cancer and night work among Norwegian nurses. Cancer Causes Control 17:39–44PubMedCrossRef

Stevens RG (2005) Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 16:254–258PubMedCrossRef

Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3:350–361PubMedCrossRef

Vitaterna MH, King DP, Chang AM et al (1994) Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 264:719–725PubMedCrossRef

Bunger MK, Wilsbacher LD, Moran SM et al (2000) Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103:1009–1017PubMedCrossRef

Dudley CA, Erbel-Sieler C, Estill SJ et al (2003) Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice. Science 301:379–383PubMedCrossRef

Zheng T, Holford TR, Mayne ST et al (2000) Risk of female breast cancer associated with serum polychlorinated biphenyls and 1,1-dichloro-2,2’-bis(p-chlorophenyl)ethylene. Cancer Epidemiol Biomarkers Prev 9:167–174PubMed

10.

Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T (2005) Period3 Structural Variation: A circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 14:268–270PubMed

11.

Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50PubMedCrossRef

12.

Johansson C, Willeit M, Smedh C et al (2003) Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 28:734–739PubMedCrossRef

13.

Lam RW, Levitan RD (2000) Pathophysiology of seasonal affective disorder: a review. J Psychiatry Neurosci 25:469–480PubMed

14.

Zhu Y, Leaderer D, Guss C et al (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin’s lymphoma. Int J Cancer 120:432–435PubMedCrossRef

15.

Walters JF, Hampton SM, Deanfield JE et al (2006) Circadian variation in endothelial function is attenuated in postmenopausal women. Maturitas 54:294–303PubMedCrossRef

16.

Koyanagi S, Kuramoto Y, Nakagawa H et al (2003) A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 63:7277–7283PubMed

17.

Wood PA, Du-Quiton J, You S, Hrushesky WJ (2006) Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 5:2023–2033PubMedCrossRef

18.

Hrushesky WJ, Bluming AZ, Gruber SA, Sothern RB (1989) Menstrual influence on surgical cure of breast cancer. Lancet 2:949–952PubMedCrossRef

19.

Retsky M, Demicheli R, Hrushesky W (2001) Breast cancer screening for women aged 40–49 years: screening may not be the benign process usually thought. J Natl Cancer Inst 93:1572PubMed

20.

Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298PubMedCrossRef

Titel: Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk
verfasst von: Yong Zhu
Richard G. Stevens
Derek Leaderer
Aaron Hoffman
Theodore Holford
Yawei Zhang
Heather N. Brown
Tongzhang Zheng
Publikationsdatum: 01.02.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9565-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Risk of neoplastic transformation in asymptomatic radial scar. Analysis of 117 cases

Estrogen receptor α polymorphisms and postmenopausal breast cancer risk

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients

Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy

Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations

An overview of prognostic factors for long-term survivors of breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie